跳至主要内容
临床试验/JPRN-UMIN000049194
JPRN-UMIN000049194已完成Unknown

Multicenter retrospective study evaluating the efficacy and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer. - NEJ056

orth East Japan Study Group0 个研究点目标入组 200 人开始时间: 2022年10月13日最近更新:

试验速览

阶段
Unknown
状态
已完成
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • (1) Patients diagnosed as having small-cell lung cancer (SCLC), combined SCLC, large-cell neuroendocrine carcinoma. (2) In both groups, patients do not meet the eligibility criteria for Durvalumab (e.g. active autoimmune disease, grade 2 or higher pneumonitis from previous CRT) (3)Patients with distant metastases at diagnosis of recurrence or at initial evaluation after chemoradiotherapy. (4)Other cases that are determined to be inappropriate by attending physicians. (5)Patients with active multiple cancers. (6) Receipt of any investigational new drugs for post-treatment.

研究者

发起方
orth East Japan Study Group

相似试验

Multicenter retrospective study evaluating the... | 临床试验